apixaban

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ESRD

Conditions

ESRD, Anticoagulant Toxicity

Trial Timeline

Sep 25, 2016 → Aug 24, 2018

NCT ID

NCT03456648

About apixaban

apixaban is a phase 2 stage product being developed by Bristol Myers Squibb for ESRD. The current trial status is completed. This product is registered under clinical trial identifier NCT03456648. Target conditions include ESRD, Anticoagulant Toxicity.

What happened to similar drugs?

4 of 8 similar drugs in ESRD were approved

Approved (4) Terminated (0) Active (4)

🔄RoxadustatAstraZenecaPhase 3

✅DoravirineMerckApproved

✅Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNINovartisApproved

✅Mycophenolic Acid (Myfortic)NovartisApproved

🔄Dianeal + Physioneal + Extraneal + NutrinealBaxterPhase 3

✅Physioneal + Dianeal + Extraneal + NutrinealBaxterApproved

🔄Dianeal + Dianeal, Extraneal, NutrinealBaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05187286	Pre-clinical	Active	—	—	—
NCT03594045	Phase 2	Terminated	Dec 18, 2018	Oct 30, 2019	Heparin-induced Thrombocytopenia
NCT02958969	Approved	Completed	Feb 28, 2018	Nov 19, 2019	Venous Thromboembolism
NCT03456648	Phase 2	Completed	Sep 25, 2016	Aug 24, 2018	ESRD
NCT02714855	Pre-clinical	Completed	Oct 1, 2015	Dec 1, 2016	Anticoagulation
NCT02345343	Pre-clinical	Completed	May 4, 2015	Oct 7, 2015	Deep Vein Thrombosis
NCT01885585	Pre-clinical	Completed	Jul 1, 2014	May 1, 2015	Venous Thromboembolism
NCT02153424	Pre-clinical	Withdrawn	Apr 1, 2014	Nov 1, 2015	Non-valvular Atrial Fibrillation (NVAF)
NCT02101112	Phase 1	Completed	Mar 1, 2014	May 1, 2014	Thrombosis
NCT01884350	Approved	Completed	Oct 15, 2013	Jan 20, 2016	Non-valvular Atrial Fibrillation
NCT01885598	Pre-clinical	Completed	Jul 10, 2013	Sep 29, 2017	NonValvular Atrial Fibrillation
NCT00252005	Phase 2	Completed	Nov 1, 2005	Feb 1, 2007	Deep-Vein Thrombosis

Competing Products

17 competing products in ESRD

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	AstraZeneca	Phase 3	40
Doravirine	Merck	Approved	43
MK-2060 + Placebo	Merck	Phase 1	29
Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI	Novartis	Approved	43
Mycophenolic Acid (Myfortic)	Novartis	Approved	43
Avacopan	Amgen	Phase 1	29
[¹⁴C]Etelcalcetide	Amgen	Phase 1	29
ISIS 416858 + Placebo	Bayer	Phase 2	32
ISIS 416858 + Placebo	Bayer	Phase 2	32
10 GE Xenokidney	United Therapeutics	Phase 1/2	36
GGTA1 KO Thymokidney	United Therapeutics	Phase 1/2	36
Dianeal + Physioneal + Extraneal + Nutrineal	Baxter	Phase 3	37
Physioneal + Dianeal + Extraneal + Nutrineal	Baxter	Approved	40
Dianeal + Dianeal, Extraneal, Nutrineal	Baxter	Phase 3	37
Acellular Tissue Engineered Vessel (ATEV)	Humacyte	Phase 3	37
Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate	Rockwell Medical	Phase 2	25
soluble ferric pyrophosphate (SFP)	Rockwell Medical	Pre-clinical	8